《Table 1 Modified UCSF down-staging criteria》
提示:宽带有限、当前游客访问压缩模式
本系列图表出处文件名:随高清版一同展现
《Hepatocellular carcinoma-time to take the ticket》
The data from the global investigation of therapeutic decision in HCC and of treatment with sorafenib(referred to as“GIDEON”)[10]have shown that the combination of TACE and sorafenib has a beneficial effect on overall survival in patients with advanced disease.The START trial[11]also supports the abovementioned finding.The SPACE trial[12]tried this combination on the Barcelona stage B HCC and did not find any difference compared to using TACE alone.Even though few of the latest studies[13]have shown benefit,further investigation is required,and feasibility of this combination for down-staging needs to be evaluated.
图表编号 | XD0077757700 严禁用于非法目的 |
---|---|
绘制时间 | 2019.06.27 |
作者 | Anju Mullath、Murali Krishna |
绘制单位 | Department of Gastroenterology, Lakeshore Hospital and Research Centre、Department of Surgery, Military Hospital |
更多格式 | 高清、无水印(增值服务) |